May 11, 2020
On Saturday, the U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) announced an allocation plan with Gilead for the drug remdesivir. The company committed to supplying approximately 607,000 vials of the experimental drug over the next six weeks to treat an estimated 78,000 hospitalized COVID-19 patients under the EUA granted by the U.S. Food and Drug Administration.
Illinois received its first shipment of remdesivir this past weekend. The shipment has been directed for distributed to hospitals that have seen the most critically ill COVID-19 patients and to safety net hospitals and hospitals treat large communities of color. See an IDPH memo on distribution methodology and hospital distribution.
To influence the government’s future remdesivir distribution, today, HHS sent an urgent message to hospital administrators requesting additional COVID-19-related information.
Hospitals are asked to log into the COVID-19 web portal at https://teletracking.protect.hhs.gov, using the same login information that was used to provide year-to-date coronavirus-related admissions. Once logged in, users will be asked to provide the number of currently hospitalized coronavirus patients, and of those admissions, the number of currently hospitalized patients requiring placement in an intensive care unit.
The newly requested information is not being captured in EMResource at this time. The Illinois Dept. of Public Health has recently been made aware of the request and urges hospitals to comply until it can confirm additional details.
Please record these values as of May 10, or the date you are submitting, prior to Tuesday, May 12 at 8 p.m. ET.